China Guillain-barre Syndrome Market Size & Outlook
Related Markets
China guillain-barre syndrome market highlights
- The China guillain-barre syndrome market generated a revenue of USD 46.7 million in 2024 and is expected to reach USD 69.0 million by 2030.
- The China market is expected to grow at a CAGR of 6.7% from 2025 to 2030.
- In terms of segment, intravenous immunoglobulin (ivig) was the largest revenue generating therapeutics in 2024.
- Plasma Exchange is the most lucrative therapeutics segment registering the fastest growth during the forecast period.
Guillain-barre syndrome market data book summary
| Market revenue in 2024 | USD 46.7 million |
| Market revenue in 2030 | USD 69.0 million |
| Growth rate | 6.7% (CAGR from 2025 to 2030) |
| Largest segment | Intravenous immunoglobulin (ivig) |
| Fastest growing segment | Plasma Exchange |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics |
Other key industry trends
- In terms of revenue, China accounted for 6.4% of the global guillain-barre syndrome market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China guillain-barre syndrome market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 46.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Guillain-Barre Syndrome Market Scope
Guillain-Barre Syndrome Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| LGM Pharma | View profile | 101-250 | Nashville, Tennessee, United States, North America | https://lgmpharma.com/ |
| Octapharma AG | View profile | 10001+ | Lachen, Schwyz, Switzerland, Europe | http://www.octapharma.com/en.html |
| Cadila Pharmaceuticals | View profile | 5001-10000 | Ahmedabad, Gujarat, India, Asia | http://cadilapharma.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
| Grifols SA Ordinary Shares - Class A | View profile | 23737 | Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, Spain, 08174 | https://www.grifols.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
China guillain-barre syndrome market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to guillain-barre syndrome market will help companies and investors design strategic landscapes.
Intravenous immunoglobulin (ivig) was the largest segment with a revenue share of 55.46% in 2024. Horizon Databook has segmented the China guillain-barre syndrome market based on intravenous immunoglobulin (ivig), plasma exchange, other therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
China is witnessing significant growth in the GBS market, driven by the increasing awareness of GBS and the growing demand for treatment options.
As more people are diagnosed with GBS, both IVIG and plasma exchange are becoming more widely used, especially in the treatment of Miller Fisher Syndrome (MFS), a rare variant of GBS.
The market is also benefiting from growing access to healthcare infrastructure, including hospital pharmacies, which provide essential treatment services for patients.
Reasons to subscribe to China guillain-barre syndrome market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China guillain-barre syndrome market databook
-
Our clientele includes a mix of guillain-barre syndrome market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China guillain-barre syndrome market , including forecasts for subscribers. This country databook contains high-level insights into China guillain-barre syndrome market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China Type - Guillain-barre Syndrome Market size, 2024 - 2030 (US$M)
China Guillain-Barre Syndrome Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
